BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Aging
    • Biosimilars
      • Artificial intelligence
    • Coronavirus
    • Israel
    • IVDs on the rise
    • Radiopharmaceuticals
    • Rise of obesity
    • Science '22 in Review
    • Top Biopharma Trends of 2022
    • Top Med-tech Trends of 2022
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • sign in
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, December 10, 2023
Home » Blogs » BioWorld MedTech Perspectives » Dinner at the end of the Medtronic Infuse story

BioWorld MedTech Perspectives
BioWorld MedTech Perspectives RSS FeedRSS

BioWorld MedTech

Dinner at the end of the Medtronic Infuse story

May 22, 2012
By Mark McCarty
No Comments

I consider myself an omnivore, but I never much cared for the taste of crow. All the same, it seems there’s some bird meat on the menu thanks to a blog I posted last year about the problems Medtronic was having with Infuse. On the other hand, I’m not alone. The U.S. Dept. of Justice has a heaping helping of the stuff on its hands.

As I wrote last August, Medtronic agreed to pay Yale University $2.5 million to review adverse events connected with Infuse, a bone morphogenic protein product that had become conspicuous for allegations that adverse events were not reliably reported by clinical trialists. Another problem was that a hefty percentage of consulting fees the firm paid in connection with the product were concentrated in what seemed a small number of doctors. That’s probably not unusual, but it looks bad under the modern med-tech microscope. A much bigger problem, however, was that a large majority of the sales volume was reported to be for off-label use.

The problem hurt Medtronic somewhat financially, including that it lost an $85 million shareholder lawsuit, but its market cap of roughly $39 billion meant the lawsuit was a bigger problem as a distraction than as a subtraction. How much the combination of lawsuit and DoJ investigation affected share prices is tough to say because the story played out over four years, but it couldn’t have come at a lousier time for anyone with a 401(k) invested in MDT.

In all fairness to my posting in 2011, I didn’t say this would kill the company or the product, and I didn’t say Medtronic was guilty of anything pernicious. What I said was the predicament suggested the need for more caution where off-label use is concerned. And I’d maintain that if more than half your sales are for off-label use … well, to use a simile the lead-footed among us can appreciate, that’s like driving a red sports car in a town where the budget is also in the red and the police are bored. You just know you’re going to get pulled over.

Now, let’s talk about Johnny Law (a.k.a. DoJ). After four years of this, that and the other thing, DoJ now says it has closed the investigation. What does the department have to show for all this? Nothing. Zip. Squadoosh. No charges and no fines. Color me cynical, but I doubt we’ll hear attorney general Eric Holder say “oops!” or “hey, real sorry about that! Still buddies, right?”

Government never makes amends when it botches things horribly, which it does with the kind of reliability that makes Old Faithful seem like just another geyser. Still, one assumes shareholders might be hacked off at DoJ’s attorneys, whose fishing expedition could not have helped anyone’s retirement plan.

I’m not arguing in favor of being able to sue government, but sometimes it seems immunity gives government attorneys too long a leash. At any rate, score one for Medtronic, and here’s to playing blogger and legal beagle. These jobs actually do put food on the table, although there’s no accounting for how appetizing that food might be.

You must login or register in order to post a comment.

Report Abusive Comment

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 8, 2023.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for December 8, 2023.
  • Stock chart with falling red arrow

    ‘Ridiculous’ site-based hitches mar Biovie phase III in Alzheimer’s

    BioWorld
    For the second time this week, a contract research organization has come under fire for trial-conduct issues – criticism leveled most recently by Biovie Inc.,...
  • Coronavirus, mRNA and syringe

    Off-target immune response from modified mRNA impacts future development

    BioWorld
    The Nobel Prize-winning modification that prevents the innate immune system from recognizing injected mRNA as foreign and blocking transcription of the protein it...
  • Feet and scale

    Waging the losing battle: Altimmune takes on challengers as Pfizer falls back

    BioWorld
    Altimmune Inc.’s peptide-based glucagon-like peptide-1/glucagon dual receptor agonist pemvidutide hiccupped in a phase I study earlier this year but has bounced...
black cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing